Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study

Chemotherapy

Volumn 53, Issue 1, 2007, Pages 44-50

  Shi, Yuankai ^a   He, Xiaohui ^a   Yang, Sheng ^a   Ai, Bin ^a   Zhang, Changgong ^a   Huang, Dingzhi ^a   Dong, Mei ^a   Liu, Peng ^a   Zhou, Shengyu ^a   Han, Xiaohong ^a  

^a CANCER HOSPITAL   (China)

Author keywords

5 Hydroxytryptamine receptor 3 antagonist; Emesis; Ondansetron; Ramosetron

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; RAMOSETRON;

ADULT; AGED; ANOREXIA; ANTIEMETIC ACTIVITY; ARTICLE; BLOATING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; INCIDENCE; LEG SWELLING; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; VOMITING;

EID: 33846429200     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098418     Document Type: Article

References (18)

1. Laszlo J: Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-949.
2. Kris MG, Gralla RJ, Clark RA, Tyson LB: Phase II trail of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 1989;81:42-46.
3. Tsavaris NB, Tsaroucha-Noutsou E, Karvounis N, Bacoyannis C, Pagou M, Kosmidis P: Comparison of different schedules of ondansetron (GR 38032F) administration during cisplatin-based chemotherapy: a randomized trial. Chemotherapy 1995;41:70-76.
4. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Kontos A, Katsorida M, Agelopoulou A, Vrizidis N, Fotia M, Papoutsis K, Koufos C: Ondansentron and dexamethasone treatment with different dosing schedules (24 versus 32 mg) in patients with non-small-cell lung cancer under cisplatin-based chemotherapy: a randomized study. Chemotherapy 2000;46:364-370.
5. 3-receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-568.
6. Lee CR, Plosker GL, McTavish D: Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an antiemetic. Drugs 1993;46:925-943.
7. Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, Yago T, Matsuda H, Ikema Y, Zhou L: A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin. Gan To Kagaku Ryoho 1995;22:1959-1967.
8. Tsukagoshi S: A new antiemetic ramosetron hydrochloride. Gan To Kagaku Ryoho 1997;24:371-380.
9. 3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum. Res Commun Mol Pathol Pharmacol 1999;104:145-155.
10. Maniovani G, Maccio A, Bianchi A, Curreli L, Ghiani M, Proto E, Santona MC: Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941-948.
11. 3 receptor antagonist, on 5-HT induced Bezold-Jarisch reflex in ferrets. Clin Rep 1994;28:2329-2335.
12. 3 receptor antagonist, on cisplatin-induced emesis in ferrets. Clin Rep 1994;28:2337-2347.
13. Akuzawa S, Ito H, Yamaguchi T: Comparative study of [3H]ramosetron and [3H]granisetron binding in the cloned human 5-hydroxytryptamine3 receptors. Jpn J Pharmacol 1998,78:381-384.
14. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, Nakajima M: Clinical phase III study of YM060 injection on anticancer drug, cisplatin-induced nausea and vomiting. Med Consult New Rem 1994;43:2241-2255.
15. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, Nakajima M: Clinical phase III study of YM060 injection on anticancer drug-induced nausea and vomiting: a double blind comparative study versus placebo. J Jpn Clin Exp Med 1994;71:2765-2776.
16. Zeng XY, Wang AH, Liu YF, Chen Y, Shen Y, Shen ZX: Ramosetron for the management of chemotherapy-induced gastrointestinal events in patients with hematological malignancies. Methods Find Exp Clin Pharmacol 2001;23:191-195.
17. Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin DB, Kim HC, Lee KH, Park YS, Lee KS, Heo DS, Kim SY, Cho EK, Lim HY, Kim WK, Lee JA, Kim TY, Lee JC, Yoon HJ, Kim NK: Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res 2002;30:220-229.
18. Feng F, Zhang P, He Y, Li Y, Zhou M, Chen G, Li L: Clinical comparison of the selective serotonin 3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia. Chin Med Sci J 2002;17:168-172.